Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Beecham switch candidates

This article was originally published in The Tan Sheet

Executive Summary

In addition to the H[2] antagonist cimeditine (Tagamet) and the smoking cessation aids Nicorette and Nicoderm from the 1992 joint venture with Marion Merrell Dow, SmithKline Beecham identifies the topical antibiotic Bactroban (mupirocin 2% ointment) as another Rx-to-OTC switch candidate in the company's 1993 annual report, In 1993, SmithKline Beecham's worldwide consumer health care business posted a 12% sales increase to nearly $2 bil., with trading profit increasing 9% to $245 mil. SmithKline's U.S. consumer health care sales of $684 mil. in 1993, which for the first time includes full-year sales from MMD's OTCs, accounted for 34% of the firm's worldwide consumer health care sales, up from 25% in 1992
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel